Neuphoria Therapeutics Inc. Common Stock
Symbol: NEUP (NASDAQ)
12.48
▲ (0.20%) 0.025
Company Description:
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Key Stats
- Today's Open: $12.96
- Today's High: $13.26
- Today's Low: $12.2
- Today's Volume: 45.67K
- Yesterday Close: $12.45
- Yesterday High: $13.25
- Yesterday Low: $11.75
- Yesterday Volume: 96.23K
- Last Min Volume: 4
- Last Min High: $12.475
- Last Min Low: $12.475
- Last Min VWAP: $12.475
Company Profile
- Name: Neuphoria Therapeutics Inc. Common Stock
- Website: https://www.bionomics.com.au
- Listed Date: 2021-12-16
- Location: BURLINGTON, MA
- Market Status: Active
- CIK Number: 0001191070
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $23.41M
- Round Lot: 100
- Outstanding Shares: 1.88M
- Asset Type: ADRC
RECENT FILINGS FOR NEUP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-23 | 424B5 | View |
| 2025-09-16 | 8-K | View |
| 2025-09-02 | 4 | View |
| 2025-07-29 | 424B5 | View |
| 2025-07-18 | 8-K | View |
| 2025-05-20 | 8-K | View |
| 2025-05-20 | 10-Q | View |
| 2025-05-19 | 4/A | View |
| 2025-05-15 | NT 10-Q | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
| 2025-02-14 | 10-Q | View |
| 2025-02-12 | 424B5 | View |
| 2025-02-04 | 424B5 | View |
| 2025-01-29 | EFFECT | View |
| 2025-01-28 | SCHEDULE 13D/A | View |